Bobart SA, et al. A target antigen-based approach to the classification of membranous nephropathy. Mayo Clin Proc 2021; 96:577–591. doi: 10.1016/j.mayocp.2020.11.028

• PubMed
Bobart SA, A target antigen-based approach to the classification of membranous nephropathy. Mayo Clin Proc 2021; 96:577–591. doi: 10.1016/j.mayocp.2020.11.028 )| false
• Search Google Scholar
• Export Citation

Caravaca-Fontán F, et al. The management of membranous nephropathy—an update. Nephrol Dial Transplant 2022; 37:1033–1042. doi: 10.1093/ndt/gfab316

• PubMed
Caravaca-Fontán F, The management of membranous nephropathy—an update. Nephrol Dial Transplant 2022; 37:1033–1042. doi: 10.1093/ndt/gfab316 )| false
• Search Google Scholar
• Export Citation

Ramachandran R, et al. Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology (Carlton) 2016; 21:139–146. doi: 10.1111/nep.12569

• PubMed
Ramachandran R, Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology (Carlton) 2016; 21:139–146. doi: 10.1111/nep.12569 )| false
• Search Google Scholar
• Export Citation

Dahan K, et al. Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 2017; 28:348–358. doi: 10.1681/ASN.2016040449

• PubMed
Dahan K, Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 2017; 28:348–358. doi: 10.1681/ASN.2016040449 )| false
• Search Google Scholar
• Export Citation

Fervenza FC, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36–46. doi: 10.1056/NEJMoa1814427

• PubMed
Fervenza FC, Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36–46. doi: 10.1056/NEJMoa1814427 )| false
• Search Google Scholar
• Export Citation

Fernández-Juárez G, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int 2021; 99:986–998. doi: 10.1016/j.kint.2020.10.014

• PubMed
Fernández-Juárez G, The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int 2021; 99:986–998. doi: 10.1016/j.kint.2020.10.014 )| false
• Search Google Scholar
• Export Citation

Scolari F, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J Am Soc Nephrol 2021; 32:972–982. doi: 10.1681/ASN.2020071091

• PubMed
Scolari F, Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J Am Soc Nephrol 2021; 32:972–982. doi: 10.1681/ASN.2020071091 )| false
• Search Google Scholar
• Export Citation

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021

• PubMed
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021 )| false
• Search Google Scholar
• Export Citation